{"id":534951,"date":"2021-03-22T20:26:01","date_gmt":"2021-03-22T20:26:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=534951"},"modified":"2021-03-22T20:26:01","modified_gmt":"2021-03-22T20:26:01","slug":"neuroendocrine-tumors-market-size-and-share-market-research-report-2030-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/neuroendocrine-tumors-market-size-and-share-market-research-report-2030-by-delveinsight_534951.html","title":{"rendered":"Neuroendocrine Tumors Market Size and Share, Market Research Report 2030 by DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1616395656.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Neuroendocrine Tumors Market Size and Share, Market Research Report 2030 by DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1616395656.jpeg\" alt=\"Neuroendocrine Tumors Market Size and Share, Market Research Report 2030 by DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8220;Neuroendocrine Tumors &#8211; Market Insights, Epidemiology, and Market Forecast-2030&#8221; report delivers an in-depth understanding of the Neuroendocrine Tumors, historical and forecasted epidemiology as well as the Neuroendocrine Tumors market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n<p style=\"text-align: justify;\">DelveInsight launched a new report on&nbsp;<span><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/neuroendocrine-tumors-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\"><strong>Neuroendocrine Tumors Market Insights, Epidemiology, and Market Forecast 2030<\/strong><\/a>.<\/span><\/p>\n<p style=\"text-align: justify;\"><span><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/3c42403abcd49dcd9b550dfe1cb9c417.jpg\" alt=\"\" \/><\/span><\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s &ldquo;<span><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/neuroendocrine-tumors-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\"><strong>Neuroendocrine Tumors Market Report 2030<\/strong><\/a>&ldquo;<\/span>&nbsp;delivers an in-depth understanding of the Neuroendocrine Tumors, historical and forecasted epidemiology as well as the Neuroendocrine Tumors market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\">Neuroendocrine tumors (NETs) are a complex group of tumors that develop predominantly in the digestive or respiratory tracts but can occur in many areas of the body.<\/p>\n<p style=\"text-align: justify;\"><strong>Request for free sample pages of the report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/neuroendocrine-tumors-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/neuroendocrine-tumors-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">The signs and symptoms associated with the disease depend on the place of origin of the tumor within the human body. At times the disease may not cause any signs or symptoms if they are slow-growing and do not secrete much of a certain hormone.<\/p>\n<p style=\"text-align: justify;\"><strong>The total prevalence of NETS was estimated at approximately&nbsp;453,191 in 2017, for 7MM.<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Key pharma players involved:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Progenics Pharmaceuticals<\/li>\n<li>Hutchison MediPharma<\/li>\n<li>Pfizer<\/li>\n<li>EpicentRx<\/li>\n<li>Amgen<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/neuroendocrine-tumors-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\"><strong>Click here and request sample pages of the report.<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">1 Key Insight<br \/>2 Executive Summary of Neuroendocrine Tumors<br \/>3 Neuroendocrine Tumors Market Overview at a Glance<br \/>4 Disease Background and Overview: Neuroendocrine Tumors<br \/>5 Case Reports<br \/>6 Neuroendocrine Tumors Epidemiology and Patient Population<br \/>7 United States Epidemiology<br \/>8 EU5 Epidemiology<br \/>9 Japan Epidemiology<br \/>10 Current Neuroendocrine Tumors Treatment and Medical Practices<br \/>11 Unmet needs<br \/>12 Neuroendocrine Tumors Marketed Drugs<br \/>13 Neuroendocrine Tumors Emerging Drugs<br \/>14 Neuroendocrine Tumors 7MM Market Analysis<br \/>15 United States<br \/>16 EU-5 countries: Market Outlook<br \/>17 Japan Market Outlook<br \/>18 Neuroendocrine Tumors Market Drivers<br \/>19 Neuroendocrine Tumors Market Barriers<br \/>20 SWOT Analysis<br \/>21 Reimbursement and market access<br \/>22 Appendix<br \/>23 DelveInsight Capabilities<br \/>24 Disclaimer<br \/>25 About DelveInsight<\/p>\n<p style=\"text-align: justify;\"><strong>Download report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/neuroendocrine-tumors-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/report-store\/neuroendocrine-tumors-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><span>About DelveInsight<\/span><br \/>DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=neuroendocrine-tumors-market-size-and-share-market-research-report-2030-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=neuroendocrine-tumors-market-size-and-share-market-research-report-2030-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight&#8217;s &#8220;Neuroendocrine Tumors &#8211; Market Insights, Epidemiology, and Market Forecast-2030&#8221; report delivers an in-depth understanding of the Neuroendocrine Tumors, historical and forecasted epidemiology as well as the Neuroendocrine Tumors market trends in the United States, EU5 &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/neuroendocrine-tumors-market-size-and-share-market-research-report-2030-by-delveinsight_534951.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-534951","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/534951","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=534951"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/534951\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=534951"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=534951"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=534951"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}